Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86

United Therapeutics Co. (NASDAQ:UTHR) has received a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $370.86.

Several analysts recently issued reports on UTHR shares. HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $400.87 on Friday. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The firm has a market cap of $17.90 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.20 and a beta of 0.56. The business has a 50 day moving average price of $360.91 and a 200-day moving average price of $325.71.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.38 EPS. Research analysts predict that United Therapeutics will post 25.1 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the sale, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 113,396 shares of company stock valued at $42,175,418 in the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. SG Americas Securities LLC lifted its stake in United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after acquiring an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares during the last quarter. Comerica Bank grew its position in United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares during the period. Tri Locum Partners LP purchased a new stake in United Therapeutics during the 2nd quarter valued at $15,959,000. Finally, QRG Capital Management Inc. boosted its stake in shares of United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after buying an additional 1,692 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.